Liminal BioSciences Inc. LMNL

RE:RE:RE:RE:RE:moving on up...........................

[PLITheOne]

OMG LOL!!

"Mark my words"
problem is that you're an idiot and have absolutely no credibility! You've been consistently wrong here with your predictions for two years now dumbazz!! :))

tommyjones0 wrote: Mark my words, this will trade between 5$-10$ easy  before the year is over!

realstocky wrote:

about 40M$ cash +100M$CAN next days from voucher confirmed so total about 140M$ at hand! WOW!!!!! Net loss is minimal and less than previous quarter : $12.6 million for the second quarter of 2021 compared to $13.2 million for the second quarter of 2020. So burn rate is now 4M$/month with about 140M$ at hand. Plenty of cash to growth the company next years, make partnerships on therapeutics, and that they have plenty, including pbi, they will announce what goes ahead soon. Market cap is only 75M$.... market cap should be 300M$..........on any news thats where its going!

 

This is bottom imo, opportunity to buy big and hold for the incoming news where this will 2x,3x,4x

 

 

 

captsecord wrote:

 

with that much cash on hand, we can wait for the news, this stock will swing huge from a market cap of 75M$. I'm expecte analysts to cover this. And when u see spammers like this after your shares, you do what they do...buy. Pbi4050 is listed on the NR as well,

 

 

Mariadelapena wrote:

 

I'm patient, and accumulating as well. Cant wait for the next news like operations update or an analyst review, at a market cap of 75M$, this will move up several fold easy!

 

captsecord wrote:

 

market cap 75M$, plenty of cash for nearly 2 years.  ALL going as best it can go. Pipeline is good, money is good, sp is extremely cheap... i'm glad im loaded!!!!

 

Key Corporate and R&D Priorities
 

• Upon closing of sale of the Rare Pediatric Disease Priority Review Voucher ("PRV") for US$105 million, Liminal will be entitled to receive an amount equal to 70% of the net proceeds, which would be payable to Liminal by its subsidiary Prometic Biotherapeutics Inc. ("PBT") prior to closing the divestment of its remaining plasma-derived therapeutics business operated through PBT to Kedrion S.p.A. ("Kedrion").
• Pending full analysis of the complete PK data set from the phase 1 multi-ascending dose ("MAD") clinical trial, we intend to determine the choice of other potential indication(s) for further development of fezagepras. No dose-limiting adverse events or other potential safety signals have been observed in the phase 1 MAD clinical trial to date.
• Pending the outcome of our pre-clinical research, and successful nomination of a pre-clinical drug candidate, we plan to initiate a pre-clinical Investigational New Drug ("IND") enabling program to support a first-in-human Phase 1 single-ascending dose clinical trial of our GPR84 antagonist drug candidate to be selected in healthy volunteers for safety and tolerability.
• Pending the outcome of our pre-clinical research, and successful nomination of a pre-clinical drug candidate, we plan to initiate a pre-clinical IND enabling program to support a first-in-human Phase 1 single-ascending dose clinical trial of our OXER1 drug candidate to be selected in healthy volunteers for safety and tolerability.

 

 

Newcamo wrote: market cap 75M$.... cash on hand 140M$.....full pipeline + full of spammers that want your shares and are buying.....